This dataset reports the daily reported number of the 7-day moving average rates of Deaths involving COVID-19 by vaccination status and by age group. Learn how the Government of Ontario is helping to keep Ontarians safe during the 2019 Novel Coronavirus outbreak. Effective November 14, 2024 this page will no longer be updated. Information about COVID-19 and other respiratory viruses is available on Public Health Ontario’s interactive respiratory virus tool: https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/Respiratory-Virus-Tool Data includes: * Date on which the death occurred * Age group * 7-day moving average of the last seven days of the death rate per 100,000 for those not fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those vaccinated with at least one booster ##Additional notes As of June 16, all COVID-19 datasets will be updated weekly on Thursdays by 2pm. As of January 12, 2024, data from the date of January 1, 2024 onwards reflect updated population estimates. This update specifically impacts data for the 'not fully vaccinated' category. On November 30, 2023 the count of COVID-19 deaths was updated to include missing historical deaths from January 15, 2020 to March 31, 2023. CCM is a dynamic disease reporting system which allows ongoing update to data previously entered. As a result, data extracted from CCM represents a snapshot at the time of extraction and may differ from previous or subsequent results. Public Health Units continually clean up COVID-19 data, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes and current totals being different from previously reported cases and deaths. Observed trends over time should be interpreted with caution for the most recent period due to reporting and/or data entry lags. The data does not include vaccination data for people who did not provide consent for vaccination records to be entered into the provincial COVaxON system. This includes individual records as well as records from some Indigenous communities where those communities have not consented to including vaccination information in COVaxON. “Not fully vaccinated” category includes people with no vaccine and one dose of double-dose vaccine. “People with one dose of double-dose vaccine” category has a small and constantly changing number. The combination will stabilize the results. Spikes, negative numbers and other data anomalies: Due to ongoing data entry and data quality assurance activities in Case and Contact Management system (CCM) file, Public Health Units continually clean up COVID-19, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes, negative numbers and current totals being different from previously reported case and death counts. Public Health Units report cause of death in the CCM based on information available to them at the time of reporting and in accordance with definitions provided by Public Health Ontario. The medical certificate of death is the official record and the cause of death could be different. Deaths are defined per the outcome field in CCM marked as “Fatal”. Deaths in COVID-19 cases identified as unrelated to COVID-19 are not included in the Deaths involving COVID-19 reported. Rates for the most recent days are subject to reporting lags All data reflects totals from 8 p.m. the previous day. This dataset is subject to change.

Note: In these datasets, a person is defined as up to date if they have received at least one dose of an updated COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that certain groups, including adults ages 65 years and older, receive additional doses.

On 6/16/2023 CDPH replaced the booster measures with a new “Up to Date” measure based on CDC’s new recommendations, replacing the primary series, boosted, and bivalent booster metrics The definition of “primary series complete” has not changed and is based on previous recommendations that CDC has since simplified. A person cannot complete their primary series with a single dose of an updated vaccine. Whereas the booster measures were calculated using the eligible population as the denominator, the new up to date measure uses the total estimated population. Please note that the rates for some groups may change since the up to date measure is calculated differently than the previous booster and bivalent measures.

This data is from the same source as the Vaccine Progress Dashboard at https://covid19.ca.gov/vaccination-progress-data/ which summarizes vaccination data at the county level by county of residence. Where county of residence was not reported in a vaccination record, the county of provider that vaccinated the resident is included. This applies to less than 1% of vaccination records. The sum of county-level vaccinations does not equal statewide total vaccinations due to out-of-state residents vaccinated in California.

These data do not include doses administered by the following federal agencies who received vaccine allocated directly from CDC: Indian Health Service, Veterans Health Administration, Department of Defense, and the Federal Bureau of Prisons.

Totals for the Vaccine Progress Dashboard and this dataset may not match, as the Dashboard totals doses by Report Date and this dataset totals doses by Administration Date. Dose numbers may also change for a particular Administration Date as data is updated.

Previous updates:

• On March 3, 2023, with the release of HPI 3.0 in 2022, the previous equity scores have been updated to reflect more recent community survey information. This change represents an improvement to the way CDPH monitors health equity by using the latest and most accurate community data available. The HPI uses a collection of data sources and indicators to calculate a measure of community conditions ranging from the most to the least healthy based on economic, housing, and environmental measures.

• Starting on July 13, 2022, the denominator for calculating vaccine coverage has been changed from age 5+ to all ages to reflect new vaccine eligibility criteria. Previously the denominator was changed from age 16+ to age 12+ on May 18, 2021, then changed from age 12+ to age 5+ on November 10, 2021, to reflect previous changes in vaccine eligibility criteria. The previous datasets based on age 16+ and age 5+ denominators have been uploaded as archived tables.

• Starting on May 29, 2021 the methodology for calculating on-hand inventory in the shipped/delivered/on-hand dataset has changed. Please see the accompanying data dictionary for details. In addition, this dataset is now down to the ZIP code level.

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

The COVID-19 Vaccination Survey in China was conducted in July 2021 to understand refugees' accessibility and willingness to receive a COVID-19 vaccination in China. UNHCR stresses that no one can be left behind in the global effort against COVID-19 and is monitoring the inclusion of refugees and asylum seekers in vaccination plans around the world. At the time, Chinese government policy did not provide free vaccines for foreigners without social security. The survey results however show that this policy was implemented with some flexibility, because among the few that were vaccinated already, more than half received a free COVID-19 vaccine. Some refugees reported difficulties or lack of information about vaccine registration or identity documents to book an appointment. Results further show that even though most are willing to get vaccinated, anti-vaccine sentiments are driven by fear of side effects.

COVID-19 Vaccination data as reported by the County's health department. On May 19, 2023, with the rescinding of the COVID-19 public health emergency, changes in data and reporting mechanisms prompted a change in the municipal counts. Data attributes listed as 'Archive Only' within the below description are reflected only in data prior to May 19, 2023. These files are maintained as 'Archive' files within this repository.

This dataset contains 3 tables:

1. Allegheny County COVID-19 Vaccine Individual Data: Contains vaccination information on an individual level for all three vaccination statuses
2. Allegheny County COVID-19 Vaccine Municipal Data: Contains counts of bivalent booster vaccinations for all neighborhoods in Allegheny County
3. Allegheny County COVID-19 Vaccine Historical Municipal Data: Contains historical counts for each vaccination status for all neighborhoods in Allegheny County up through May 2023, then limited to counts of bivalent booster vaccinations following this cut-off.

Types of Vaccination Status:

1. Partially Vaccinated [Individual and Archive Only]: If an individual has not completed their primary series with either 1 of 2-dose series or 2 of 3-dose series for children under the age of 5 years
2. Completed Primary Series (formerly Fully Vaccinated) [Individual and Archive Only]: If an individual has completed their primary series with the 1-dose J&J series, 2-dose series, or 3-dose series for children under 5 years.
3. Bivalent Booster: If an individual has obtained their bivalent booster dose.

Due to minor discrepancies in the Municipal boundary and the City of Pittsburgh Neighborhood files individuals whose City Neighborhood cannot be identified are be counted as “Undefined (Pittsburgh)”.

Support for Health Equity datasets and tools provided by Amazon Web Services (AWS) through their Health Equity Initiative.

Vaccination against COVID-19 is making progress globally, but vaccine doses remain a rare commodity in many parts of the world. New virus variants mean that updated vaccines become available more slowly. Policymakers have defined criteria to regulate who gets priority access to the vaccination, such as age, health complications, or those who hold system-relevant jobs. But how does the public think about vaccine allocation? To explore those preferences, we surveyed respondents in Brazil, Germany, Italy, Poland, and the United States from September to December of 2020 using ranking and forced-choice tasks. We find that public preferences are consistent with expert guidelines prioritizing health care workers and people with medical preconditions. However, the public also considers those signing up early for vaccination and citizens of the country to be more deserving than later-comers and non-citizens. These results hold across measures, countries, and socio-demographic subgroups.

Deprecated as of 4/21/2023On 4/27/2023 several COVID-19 datasets were retired and no longer included in public COVID-19 data dissemination. For more information, visit https://imap.maryland.gov/pages/covid-dataSummaryThe cumulative number of COVID-19 vaccinations for persons aged 65+ within a single Maryland jurisdiction: Persons fully vaccinated and those who have received at least one dose.DescriptionThe MD COVID-19—Persons 65+ Fully Vaccinated layer represents the number of people in each Maryland jurisdiction aged 65 and older who have either received at least one dose of COVID-19 vaccine in a two-dose regimen or are fully vaccinated (have either received a single shot regimen or have completed the second dose in a two-dose regimen), reported each day into ImmuNet.CDC COVID10 Vaccinations in the United States,CountyCOVID-19 is a disease caused by a respiratory virus first identified in Wuhan, Hubei Province, China in December 2019. COVID-19 is a new virus that hasn't caused illness in humans before. Worldwide, COVID-19 has resulted in thousands of infections, causing illness and in some cases death. Cases have spread to countries throughout the world, with more cases reported daily. The Maryland Department of Health reports daily on COVID-19 cases by county.

JHU Has Stopped Collecting Data As Of 03/10/2023

After three years of around-the-clock tracking of COVID-19 data from around the world, Johns Hopkins has discontinued the Coronavirus Resource Center’s operations.

The site’s two raw data repositories will remain accessible for information collected from 1/22/20 to 3/10/23 on cases, deaths, vaccines, testing and demographics.

Novel Corona Virus (COVID-19) epidemiological data since 22 January 2020. The data is compiled by the Johns Hopkins University Center for Systems Science and Engineering (JHU CCSE) from various sources including the World Health Organization (WHO), DXY.cn, BNO News, National Health Commission of the People’s Republic of China (NHC), China CDC (CCDC), Hong Kong Department of Health, Macau Government, Taiwan CDC, US CDC, Government of Canada, Australia Government Department of Health, European Centre for Disease Prevention and Control (ECDC), Ministry of Health Singapore (MOH), and others. JHU CCSE maintains the data on the 2019 Novel Coronavirus COVID-19 (2019-nCoV) Data Repository on Github.

Fields available in the data include Province/State, Country/Region, Last Update, Confirmed, Suspected, Recovered, Deaths.

On 23/03/2020, a new data structure was released. The current resources for the latest time series data are:

• time_series_covid19_confirmed_global.csv
• time_series_covid19_deaths_global.csv
• time_series_covid19_recovered_global.csv

---DEPRECATION WARNING---
The resources below ceased being updated on 22/03/2020 and were removed on 26/03/2020:

• time_series_19-covid-Confirmed.csv
• time_series_19-covid-Deaths.csv
• time_series_19-covid-Recovered.csv

China COVID-19: Vaccinated People: Booster Shots: To-Date data was reported at 827.904 Person mn in 27 Apr 2023. This records an increase from the previous number of 827.839 Person mn for 20 Apr 2023. China COVID-19: Vaccinated People: Booster Shots: To-Date data is updated daily, averaging 793.279 Person mn from Nov 2021 (Median) to 27 Apr 2023, with 51 observations. The data reached an all-time high of 827.904 Person mn in 27 Apr 2023 and a record low of 37.973 Person mn in 05 Nov 2021. China COVID-19: Vaccinated People: Booster Shots: To-Date data remains active status in CEIC and is reported by National Health Commission. The data is categorized under China Premium Database’s Socio-Demographic – Table CN.GZ: COVID-19: Vaccination.

While mass vaccination campaigns against COVID-19 have inoculated almost 200 million Americans and billions more worldwide, significant pockets of vaccine hesitancy remain. Research has firmly established that vaccine efficacy is an important driver of public vaccine acceptance and choice. However, current vaccines offer widely varying levels of protection against different adverse health outcomes of COVID-19. This study employs an experiment embedded on a survey of 1,194 US adults in June 2021 to examine how communications about vaccine efficacy affect vaccine choice. The experiment manipulated how vaccine efficacy was defined across four treatments: (1) protection against symptomatic infection; (2) protection against severe illness; (3) protection against hospitalization/death; (4) efficacy data on all three metrics. The control group received no efficacy information. Subjects were asked to choose between a pair of vaccines—a one-dose viral vector vaccine or two-dose mRNA vaccine—whose efficacy data varied across the four experimental treatment groups. Efficacy data for each vaccine on each dimension were adapted from clinical trial data on the Johnson & Johnson/Janssen and Pfizer/BioNTech vaccines. Among all respondents, only modest preference gaps between the two vaccines emerged in the control group and when the two vaccines’ roughly equivalent efficacy data against hospitalization and death were reported. Strong preferences for a two-dose mRNA vaccine emerged in treatments where its higher efficacy against symptomatic or severe illness was reported, as well as in the treatment where data on all three efficacy criteria were reported. Unvaccinated respondents preferred a one-dose viral vector vaccine when only efficacy data against hospitalization or death was presented. Black and Latino respondents were significantly more likely to choose the one-shot viral vector vaccine in the combined efficacy treatment than were whites. Results speak to the importance of understanding how communications about vaccine efficacy affect public preferences in an era of increasing uncertainty about efficacy against variants.

SummaryThe cumulative number of COVID-19 vaccinations for persons aged 65+ within a single Maryland jurisdiction: Persons fully vaccinated and those who have received at least one dose.DescriptionThe MD COVID-19—Persons 65+ Fully Vaccinated layer represents the number of people in each Maryland jurisdiction aged 65 and older who have either received at least one dose of COVID-19 vaccine in a two-dose regimen or are fully vaccinated (have either received a single shot regimen or have completed the second dose in a two-dose regimen), reported each day into ImmuNet.COVID-19 is a disease caused by a respiratory virus first identified in Wuhan, Hubei Province, China in December 2019. COVID-19 is a new virus that hasn't caused illness in humans before. Worldwide, COVID-19 has resulted in thousands of infections, causing illness and in some cases death. Cases have spread to countries throughout the world, with more cases reported daily. The Maryland Department of Health reports daily on COVID-19 cases by county.

BackgroundSARS-CoV-2 vaccines are safe and effective against infection and severe COVID-19 disease worldwide. Certain co-morbid conditions cause immune dysfunction and may reduce immune response to vaccination. In contrast, those with co-morbidities may practice infection prevention strategies. Thus, the real-world clinical impact of co-morbidities on SARS-CoV-2 infection in the recent post-vaccination period is not well established. This study was performed to understand the epidemiology of Omicron breakthrough infection and evaluate associations with number of comorbidities in a vaccinated and boosted population.Methods and findingsA retrospective clinical cohort study was performed utilizing the Northwestern Medicine Enterprise Data Warehouse. Our study population was identified as fully vaccinated adults with at least one booster. The primary risk factor of interest was the number of co-morbidities. The primary outcome was the incidence and time to the first positive SARS-CoV-2 molecular test in the Omicron predominant era. Multivariable Cox modeling analyses to determine the hazard of SARS-CoV-2 infection were stratified by calendar time (Period 1: January 1 –June 30, 2022; Period 2: July 1 –December 31, 2022) due to violations in the proportional hazards assumption. In total, 133,191 patients were analyzed. During Period 1, having 3+ comorbidities was associated with increased hazard for breakthrough (HR = 1.16 CI 1.08–1.26). During Period 2 of the study, having 2 comorbidities (HR = 1.45 95% CI 1.26–1.67) and having 3+ comorbidities (HR 1.73, 95% CI 1.51–1.97) were associated with increased hazard for Omicron breakthrough. Older age was associated with decreased hazard in Period 1 of follow-up. Interaction terms for calendar time indicated significant changes in hazard for many factors between the first and second halves of the follow-up period.ConclusionsOmicron breakthrough is common with significantly higher risk for our most vulnerable patients with multiple co-morbidities. Age plays an important role in breakthrough infection with the highest incidence among young adults, which may be due to age-related behavioral factors. These findings reflect real-world differences in immunity and exposure risk behaviors for populations vulnerable to COVID-19.

On March 10, 2023, the Johns Hopkins Coronavirus Resource Center ceased collecting and reporting of global COVID-19 data. For updated cases, deaths, and vaccine data please visit the following sources:Global: World Health Organization (WHO)U.S.: U.S. Centers for Disease Control and Prevention (CDC)For more information, visit the Johns Hopkins Coronavirus Resource Center.This feature layer contains the most up-to-date COVID-19 cases for the US and Canada. Data sources: WHO, CDC, ECDC, NHC, DXY, 1point3acres, Worldometers.info, BNO, state and national government health departments, and local media reports. This layer is created and maintained by the Center for Systems Science and Engineering (CSSE) at the Johns Hopkins University. This feature layer is supported by the Esri Living Atlas team and JHU Data Services. This layer is opened to the public and free to share. Contact Johns Hopkins.IMPORTANT NOTICE: 1. Fields for Active Cases and Recovered Cases are set to 0 in all locations. John Hopkins has not found a reliable source for this information at the county level but will continue to look and carry the fields.2. Fields for Incident Rate and People Tested are placeholders for when this becomes available at the county level.3. In some instances, cases have not been assigned a location at the county scale. those are still assigned a state but are listed as unassigned and given a Lat Long of 0,0.Data Field Descriptions by Alias Name:Province/State: (Text) Country Province or State Name (Level 2 Key)Country/Region: (Text) Country or Region Name (Level 1 Key)Last Update: (Datetime) Last data update Date/Time in UTCLatitude: (Float) Geographic Latitude in Decimal Degrees (WGS1984)Longitude: (Float) Geographic Longitude in Decimal Degrees (WGS1984)Confirmed: (Long) Best collected count of Confirmed Cases reported by geographyRecovered: (Long) Not Currently in Use, JHU is looking for a sourceDeaths: (Long) Best collected count for Case Deaths reported by geographyActive: (Long) Confirmed - Recovered - Deaths (computed) Not Currently in Use due to lack of Recovered dataCounty: (Text) US County Name (Level 3 Key)FIPS: (Text) US State/County CodesCombined Key: (Text) Comma separated concatenation of Key Field values (L3, L2, L1)Incident Rate: (Long) People Tested: (Long) Not Currently in Use Placeholder for additional dataPeople Hospitalized: (Long) Not Currently in Use Placeholder for additional data

No description was included in this Dataset collected from the OSF

Abstract

A strong evidence base is needed to understand the socioeconomic implications of the coronavirus pandemic for the Solomon Islands. High Frequency Phone Surveys (HFPS) are set up to understand these implications over the years. This data is the fifth of the five planned rounds of mobile surveys. Four rounds of the HFPS are already completed in June 2020 (Round 1), Dec 2020-Jan 2021 (Round 2), July-Aug 2021 (Round 3) and Jan 2022-Feb 2022 (Round 4), Round 5 interviewed 2,507 households across the country between July 30, 2022, and September 8, 2022, on topics including vaccines of COVID-19, employment, income, food security, health, and coping strategies, and public trust and security.

Geographic coverage

Urban and rural areas of Solomon Islands.

Analysis unit

Household and Individual.

Universe

All respondents must be aged 18 and over and have a phone.

Kind of data

Sample survey data [ssd]

Sampling procedure

As the objective of the survey was to measure changes as the pandemic progresses, Round Five data collection sought to re-contact all 2,671 households contacted in Round Four. The protocols for re-contact were a maximum of 3 attempts per caller shift, spaced between 1.5 and 2.5 hours apart depending on whether the phone was busy or there was no answer, and 15 attempts in total. A new survey company (Sistemas) was hired for the fifth round, and the old survey company (Tebbutt) did not provide the phone numbers of the old households contacted in previous rounds. Hence, no returning households can be identified in round 5. In Round Five, Honiara was over-represented in the World Bank HFPS (constituting 47.7 percent of the survey sample). All other provinces were deemed under-represented, with the largest differences being for Malaita and Western, which represented 9.5 percent (Census: 21.4 percent), and 12.5 percent of the survey sample (Census: 21.4 percent), respectively. Urban areas constituted 58.3 percent of the survey sample, compared to a quarter (25.6 percent) of the census. The target geographic distribution for the survey was based on the population distribution across provinces from the preliminary 2019 census results. According to the population census, Honiara constituted almost one quarter (18.0 percent) of the total population. Compensating factors for these differences were developed and included in the re-weighting calculations.

Due to the limited sample sizes outside of Honiara, most results are disaggregated into only three geographic regions: Honiara, other urban areas, and rural areas. For more information on sampling, please refer to the presentation slides provided in the External Resources.

Mode of data collection

Computer Assisted Telephone Interview [cati]

Research instrument

The questionnaire - that can be found in the External Resources of this documentation - was developed both in English and in Solomons Pijin. The survey instrument for the fifth round consisted of the following modules: -Basic information, -Information about COVID-19, -Vaccines of COVID-19, -Health, -Education, -Access food & food security, -Employment and Income, -Coping strategies, -Public trust and security, -and Assets and wellbeing.

Cleaning operations

At the end of data collection, the dataset was cleaned by the World Bank team. This included formatting, and correcting results based on monitoring issues, enumerator feedback and survey changes. Data was edited using Stata.
The data is presented in three data sets: household data set, individual data set, and child data set. The total number of observations in the household data set is 2,507 in the individual data set and is 1,260 in the child data set. The child data set contains the education information for children of all households who answered this section, the individual data set contains the employment and vaccine information for all individuals, and the household data set contains information about health, access food & food security, coping strategies, public trust and security, and assets and well-being.

National Health Service data on vaccination status. Age and nationality according to the Population Register data. Persons who, according to the CSB data, were not permanent residents of Latvia at the beginning of the year are not included. Residents who have passed 14 days after completing a complete primary vaccination series or receiving a single dose of a vaccine following a laboratory-confirmed positive COVID-19 test (comply with the conditions necessary for obtaining a vaccination certificate, more broadly) are accepted as fully vaccinated. For monthly relative data, the total population at the beginning of the respective year is used, and those who died between the beginning of the year and the respective month are not included among the vaccinated population. More on how to measure population and key demographic indicators in experimental statistics descriptive metadata. Structural metadata. The calculation of experimental statistics uses new data sources and methods, seeking to broaden the range or level of detail of statistics according to the needs of users. It should be noted that experimental statistical methods are not unchanged, approbated and internationally agreed and may be changed in order to improve data quality. The CSB publishes experimental statistics in order to receive user feedback, evaluate the analytical potential of the data, compliance with reality and user needs. The CSB considers that the time series of experimental data can also be useful for users and the opinion of users of statistics is the basis for the decision to include these statistics in the Official Statistics Programme. When publishing experimental statistics, the CSB provides data users with new sources of information for decision-making.

COVID-19 vaccine rollout in Kenya has been challenged by both the supply of and demand for vaccines. With a third of the adult population classifying as vaccine hesitant, reaching vaccination targets requires an understanding of how people make decisions regarding vaccines. Globally, pregnant and lactating women have especially low uptake rates, which could be attributed to the “infodemic,” or constant rush of new information, as this group is vulnerable to misinformation and uncertainty. While presentation of COVID-19 vaccines in the media allows for easy access, these sources are also susceptible to misinformation. Negative and unfounded claims surrounding SARS-CoV-2 infection and COVID-19 vaccines contribute to vaccine hesitancy. Given the influence that the media may have on people's attitudes toward vaccines, this study examines the relationship between the media and the vaccine decision-making process among pregnant and lactating women, healthcare workers, community members (male relatives, male neighbors, and gatekeepers), and policymakers in Kenya. Data were collected through in-depth interviews in urban and rural counties in Kenya to understand how media information was utilized and consumed. While healthcare workers were the most frequently cited information source for pregnant and lactating women, other healthcare workers, and community members, findings also show that the media (traditional, social, and Internet) is an important source for obtaining COVID-19 information for these groups. Policymakers obtained their information most frequently from traditional media. Ensuring that information circulating throughout these media channels is accurate and accessible is vital to reduce vaccine hesitancy and ultimately, meet COVID-19 vaccination goals in Kenya.

BackgroundA vaccine against COVID-19 is a vital tool in managing the current pandemic. It is becoming evident that an effective vaccine would be required to control COVID-19. Effective use of vaccines is very important in controlling pandemics and paving the way for an acceptable exit strategy. Therefore, this systematic review and meta-analysis aims to determine the global COVID-19 acceptance rate that is necessary for better management of COVID-19 pandemic.MethodsThis review was conducted based on Preferred Reporting Items for Systematic Reviews and Meta-Analysis protocols and considered the studies conducted on acceptance and/or hesitancy of COVID-19 vaccine. Articles were searched using electronic databases including PubMed, Scopus, Web of Science, Embase, CINAHL, and Google Scholar. The quality of the study was assessed using the Joanna Briggs Institute (JBI) critical assessment tool to determine the relevance of each included article to the study.ResultsOf the 6,021 articles identified through the electronic database search, 68 articles were included in the systematic review and meta-analysis. The global pooled acceptance rate of the COVID-19 vaccine was found to be 64.9% [95% CI of 60.5 to 69.0%]. Based on the subgroup analysis of COVID-19 vaccine acceptance rate by the World Health Organization's region, the countries where the study was conducted, occupation, and survey period, the prevalence of COVID-19 vaccine acceptance rate was 60.8% [95% CI: 56.3, 65.2%], 61.9% [95% CI: 61.3, 62.4%], 81.6% [95% CI: 79.7, 83, 2%] and 64.5% [95% CI: 60.3, 68.5%], respectively.ConclusionsThis review revealed the variation in the level of COVID-19 vaccine acceptance rate across the world. The study found that the overall prevalence of COVID-19 vaccine acceptance was 64.9%. This finding indicated that even if the COVID-19 vaccine is developed, the issue of accepting or taking the developed vaccine and managing the pandemic may be difficult.

China COVID-19: Vaccinated People: To-Date data was reported at 1,310.489 Person mn in 27 Apr 2023. This records an increase from the previous number of 1,310.480 Person mn for 20 Apr 2023. China COVID-19: Vaccinated People: To-Date data is updated daily, averaging 1,293.447 Person mn from Jun 2021 (Median) to 27 Apr 2023, with 59 observations. The data reached an all-time high of 1,310.489 Person mn in 27 Apr 2023 and a record low of 622.000 Person mn in 10 Jun 2021. China COVID-19: Vaccinated People: To-Date data remains active status in CEIC and is reported by National Health Commission. The data is categorized under China Premium Database’s Socio-Demographic – Table CN.GZ: COVID-19: Vaccination.

BackgroundCOVID-19 has caused a global pandemic and the death toll is increasing. With the coronavirus continuously mutating, Omicron has replaced Delta as the most widely reported variant in the world. Studies have shown that the plasma of some vaccinated people does not neutralize the Omicron variant. However, further studies are needed to determine whether plasma neutralizes Omicron after one- or two-dose vaccine in patients who have recovered from infection with the original strain.MethodsThe pseudovirus neutralization assays were performed on 64 plasma samples of convalescent COVID-19 patients, which were divided into pre-vaccination group, one-dose vaccinated group and two-dose vaccinated group.ResultsIn the three groups, there were significant reductions of sera neutralizing activity from WT to Delta variant (B.1.617.2), and from WT to Omicron variant (B.1.1.529) (ps0.05). The average neutralization of the Omicron variant showed a significant difference between pre-vaccination and two-dose vaccinated convalescent individuals (p